Aarkstore Enterprise
BIOSIMILARS: US PAYER PERSPECTIVES Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers. While the number of biosimilar approvals in the US still lags behind Europe, a solid foundation continues to be laid by multiple key stakeholder groups. Successes have been seen in key areas, including the approval of the first monoclonal antibody (mAb) biosimilar, Inflectra, and regulatory refinement. But what of the critical opportunities and challenges in the US? How do payers perceive what’s important, and what can companies do to ensure commercial success?
WHAT FEATURES DOES THE REPORT PROVIDES? In-depth interviews reveal over 200 unique and candid insights from ten 10 expert US payers from government and commercial backgrounds Overview of the key areas of progress in the US biosimilars market during the last year, including an analysis of critical market shaping issues such as clinical data, regulatory progress, commercialisation, legal and policy. The key issues regarding how the US biosimilars market has evolved and where payers believe future efforts need to be focused, including pricing, market access and contracting.
Aarkstore Enterprise
Detailed case studies on the commercialisation of two biosimilars (Zarxio and Inflectra) and one follow-on biologic (Basaglar), and what payers believe has gone well and where improvements for subsequent launches need to be made. Updated insights on what the critical challenges and opportunities within the US biosimilars market are today, and what companies can do to navigate these successfully.
WHAT ARE THE KEY BENEFITS OF THE REPORT ? Understand how the US biosimilars market has evolved over the past year and what the stand- out developments was. Gain insight into the trends that are set to drive high rates of biosimilar adoption in the US, and what issues could slow this adoption down Gain insight into the role of focused and unbiased education has on biosimilars, and which key stakeholder group payers believe needs to be the key focus of these educational efforts. Assess the current views on drug pricing in the US, and what impact biosimilars could have on lowering prices and improving patient access. Critique payer views on the evolving arguments for switching from originator brands to biosimilars, and how FDA regulations and state-level legislation needs to work in concert for this to become a reality. Navigate the critical opportunities and challenges within the US biosimilars market, and understand what payers see as must-win battles to ensure a successful US biosimilars market.
WHAT ARE THE KEY QUESTIONS ANSWERED IN THIS REPORT? How have the key drivers and resistors of biosimilar usage in the US evolved over the past year?
Aarkstore Enterprise
Do payers agree with the current regulatory pathway for biosimilars in the US, and how do they perceive it changing moving forward, particularly in relation to interchangeability? How do payers expect pricing dynamics within the US biosimilars market to evolve, and what are their expectations in relation to the pricing of originator biologics in response to biosimilar competition? How have payer views in relation to the key market-shaping issues of switching, automatic substitution, extrapolation of indications, and biosimilar naming changed over the past year, and how have key events in these areas shaped and changed thinking? What does the future hold for biosimilars in the US; is it a case that biosimilars need to succeed in order to support a more sustainable healthcare system, or will the biosimilars market crumble under the weight of its own expectations?
WHO WOULD BENEFIT FROM THIS REPORT? Commercial teams negotiating biosimilar prices and discounts with payers Marketing teams communicating the benefits and safety of biosimilars Medical affairs teams, including medical science liaisons, who are building the evidence case for biosimilars with physicians and payers, and engaging with physicians about biosimilar safety and efficacy Market research and HEOR teams analysing long-term real world data on biosimilar use and outcomes Payer strategy teams tasked with the job of understanding what payers are looking for from biosimilars and originator brands, and how this thinking can be change
Aarkstore Enterprise
YOU CAN ORDER FULL REPORT @BIOSIMILARS: US PAYER PERSPECTIVES TABLE OF CONTENT 1. Executive Summary 2. Research Objectives and Methodology 3. Overview Of Progress In The Us Market 4. Biosimilar Awareness and Education 5. The Currently Regulatory Environment 6. Key Considerations in The Commercialisation Of Biosimilars 7. Biosimilar Commercialisation Case Studies 8. Future Challenges and Opportunities 9. Appendix
MORE RELATED REPORTS @ HEALTHCARE MARKET RESEARCH REPORTS ABOUT AARKSTORE ENTERPRISE Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
CONTACT DETAILS: Aarkstore Enterprise
Aarkstore Enterprise
Phone: +91 998 729 5242 / +91 - 22 2756 4953
EMAIL: ENQUIRY@AARKSTORE.COM OUR WEBSITE: HTTP://WWW.AARKSTORE .COM OUR BLOG: HTTP://WWW.AARKSTORE .COM/BLOG/ OUR NEWS SECTION: HTTP://WWW.AARKSTORE .COM/NEWS